RJA
OGEN icon

Raymond James & Associates’s Oragenics OGEN Stock Holding History

Raymond James & Associates’s Portfolio OGEN Stock Details OGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19
Closed -$3.56K – 4013
2022
Q4 		$3.56K Buy
+19
New +$6.71K ﹤0.01% 3890

Other funds holding OGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return

Raymond James & Associates's OGEN Position: Q1 2023 in Review

Raymond James & Associates sold out of Oragenics (OGEN) in Q1 2023, closing a stake of 19 shares — an estimated $3.56K sold.

Raymond James & Associates first reported a position in OGEN in Q4 2022 and held it in 1 quarter. The position peaked at $3.56K in Q4 2022. 10 funds tracked by Wall St. Rank hold OGEN as of Q1 2023.

  • Raymond James & Associates reported no remaining Oragenics position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 19 Oragenics shares in Q1 2023, an estimated $3.56K.
  • Raymond James & Associates first reported a position in Oragenics in Q4 2022 and held it in 1 quarter.
  • Raymond James & Associates's Oragenics position peaked at $3.56K in Q4 2022.
  • 10 funds tracked by Wall St. Rank held Oragenics as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.